Abstracts tagged "autoimmune diseases"

Abstract Number: 0740 • ACR Convergence 2022
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
Carl Allen¹, Shanmuganathan Chandrakasan², Michael Jordan³, Jennifer Leiding⁴, Abiola Oladapo⁵, Priti Pednekar⁶, Kelly Walkovich⁷ and John Yee⁸, ¹Baylor College of Medicine, Houston, TX, ²Emory University School of Medicine, Atlanta, GA, ³University of Cincinnati, Cincinnati, OH, ⁴Johns Hopkins University, Baltimore, MD, ⁵Swedish Orphan Biovitrum AB, Boston, MA, ⁶PRECISIONheor, Los Angeles, CA, ⁷University of Michigan Health, Ann Arbor, MI, ⁸Sobi - North America, Waltham, MA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome caused by overproduction of proinflammatory cytokines, e.g., interferon gamma (IFNγ). Secondary HLH (sHLH), a subtype…
Abstract Number: 0790 • ACR Convergence 2022
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
Omar Alsaed, Masautso Chaponda, Eman Satti, Hadil Ashour, Muna Almaslamani and Samar Al emadi, Hamad Medical Corporation, Doha, Qatar
Background/Purpose: The sustainability of the immunogenicity of BNT162b2 anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune rheumatic diseases (ARDs) receiving immunomodulators…
Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Stacey Dillon¹, Pille Harrison², Jason Lickliter³, Kristi Manjarrez¹, Alina Smith¹, Mary Lessig¹, Lori Blanchfield¹, Russell Sanderson¹, Allison Chunyk¹, Tiffany Blair¹, Amanda Enstrom¹, Martin Wolfson¹, Mark Rixon¹, Hany Zayed⁴, Rupert Davies¹ and Stanford Peng¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Taunton, United Kingdom, ³Nucleus Network, Melbourne, Australia, ⁴Alpine Immune Sciences, San Francisco, CA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…
Abstract Number: 1200 • ACR Convergence 2022
Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years
Karen Costenbader¹, Nancy R Cook², I-Min Lee², Jill Hahn³, Joseph Walter¹, Vadim Bubes¹, Gregory Kotler¹, Nicole Yang¹, Sonia Friedman¹, Erik K Alexander¹ and JoAnn E Manson², ¹Brigham and Women's Hospital, Boston, MA, ²Harvard TH Chan School of Public Health, Brigham and Women's Hospital, Boston, MA, ³Brigham and Womens' Hospital, Boston, MA
Background/Purpose: Strong biologic rationale supports potential effects of both vitamin D and of marine omega-3 (n3) fatty acids for autoimmune disease prevention. Within the randomized…
Abstract Number: 1363 • ACR Convergence 2022
Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies
Jessica Perfetto¹, Donna Yoo², Carolina Tamashiro³, Megan Perron⁴, Natalia Vasquez Canizares⁵ and Dawn Wahezi⁶, ¹The Children's Hospital at Montefiore, Division of Rheumatology, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³The Children's Hospital at Montefiore, Department of Pediatrics, Bronx, NY, ⁴Children's Hospital Colorado, Division of Rheumatology, Aurora, CO, ⁵Children's Hospital at Montefiore/ Albert Einstein College of Medicine, New York, NY, ⁶Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: Viruses can trigger juvenile idiopathic inflammatory myopathies (JIIM), including juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), and overlap myositis. There is growing evidence that infection…
Abstract Number: 1662 • ACR Convergence 2022
Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern
Noelle Kosarek¹, Megan Romano², Robert Simms³, Angeline Andrew⁴, Erika Moen⁴, Patricia pioli⁴ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and autoantibody formation. The etiology…
Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Felix Chin⁶, Thomas Vazquez⁷ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷FIU Wertheim College of Medicine, Virginia Beach, VA
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…
Abstract Number: 2191 • ACR Convergence 2022
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
In Ah Choi¹, Ji Hyoun Kim², Sung Hae Chang³, Hyun Jung Kim⁴ and Hyeong Sik Ahn⁴, ¹Chungbuk National University, Cheongju, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ⁴Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
Abstract Number: 0042 • ACR Convergence 2022
The Pathogenic Role of Lymphatic Vessels in Autoimmune Valvular Carditis
Amritha Yellamilli¹, Victoria Osinski², Maria Firulyova³, Jennifer Auger⁴, Lee Meier², Jessica Faragher⁵, Aubyn Marath⁶, Konstantin Zaitsev³ and Bryce Binstadt⁵, ¹Stanford University School of Medicine, Palo Alto, ²University of Minnesota School of Medicine, Minneapolis, MN, ³ITMO University, Saint Petersburg, Russia, ⁴University of Minnesota Medical School, Minneapolis, MN, ⁵University of Minnesota, Minneapolis, MN, ⁶CardioStart, Portland
Background/Purpose: Valvular carditis is a serious complication of systemic autoimmune diseases. Although endothelial cells are thought to play an important role in autoimmune valvular carditis,…
Abstract Number: 0161 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
DeAnna Diaz¹, Thomas Vazquez², Nilesh Kodali³, Madison Grinnell⁴, Emily Keyes⁴, Josh Dan⁴, Grant Sprow⁵, Muhammad Bashir⁶, Meena Sharma⁷ and Victoria Werth⁸, ¹Philadelphia College of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³New Jersey Medical School, Coppell, TX, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁸University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. Lenabasum, a non-psychoactive cannabinoid type 2 receptor (CB2R) agonist, is…
Abstract Number: 0555 • ACR Convergence 2022
Heterogeneity in Origin and Function of Distinct Human Synovial-tissue Dendritic Cells in Health, Active Rheumatoid Arthritis (RA) and RA in Disease Remission
Aziza Elmesmari¹, Lucy MacDonald², Jack Frew², Domenico Somma², Clara Di Mario³, Audrey Paoletti⁴, Diane Vaughan⁵, Barbara Tolusso⁶, Simone Perniola⁶, Marco Gessi⁷, Leandro Lemgruber⁵, Maria Rita Gigante⁸, Luca P Petricca⁹, Laura Bui⁷, Dario Bruno³, charles McSharry⁵, John D Isaacs¹⁰, Iain B McInnes¹¹, Simon Milling⁵, Elisa Gremese³, Thomas D Otto², Kenneth Baker¹², Stefano Alivernini⁶ and Mariola Kurowska-Stolarska¹, ¹Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, Scotland, United Kingdom, ²Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, Scotland, United Kingdom, ³Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴University of Glasgow, Glasgow, Scotland, United Kingdom, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ⁷Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ⁸Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, United Kingdom, ⁹Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ¹⁰Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, ¹¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ¹²Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle, United Kingdom
Background/Purpose: Current treatments for RA do not restore the immune tolerance characteristic of health. Dendritic cells (DC) are one of the cell types that can…
Abstract Number: 0651 • ACR Convergence 2022
Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis
Latha Prabha Ganesan, Shane Bruckner, Noushin Saljoughian, James Turman, Murugesan Rajaram, Brad Rovin, Wael Jarjour and Samir Parikh, The Ohio State University, Columbus, OH
Background/Purpose: The pathogenesis of lupus nephritis (LN) is incompletely understood stalling progress and resulting in suboptimal patient outcomes. We previously identified a novel inflammatory dendritic…
Abstract Number: 0741 • ACR Convergence 2022
Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease
Emily G Oakes¹, Jack Ellrodt¹, May Choi², Hongshu Guan¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i, dapagliflozin, canagliflozin, and empagliflozin) are a class of oral hypoglycemic medication for management of Type II diabetes mellitus (T2D),…
Abstract Number: 0792 • ACR Convergence 2022
Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
Margaret Ma¹, Amelia Santosa¹, Kok Ooi Kong², Chuanhui Xu², Gim Gee Teng¹, Johnston GX Tang², Anselm Mak³, Frank Tay¹, Victoria WW Ng⁴, Joshua ZE Koh⁴, Warren Fong⁵, Li-Ching Chew⁶, Andrea Low⁷, annie law⁸, Yih Jia Poh⁸, Siaw Ing Yeo⁶, Ying Ying Leung⁹, Wei-Rui Goh⁶, Nur Emilia Roslan¹⁰, Tyng Yu Chuah¹⁰, Stanley Angkodjojo¹¹, Thaschawee Arkachaisri¹², Kai Liang Teh¹³, Kee Fong Phang¹⁴, Melonie Sriranganathan¹⁵, teck Choon Tan¹⁶, Peter Cheung¹ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁴National University of Singapore, Singapore, Singapore, ⁵Singapore Health Services Pte Ltd (SHS), Singapore, Singapore, ⁶Singapore General Hospital, Singapore, Singapore, ⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁸SingHealth, Singapore, Singapore, ⁹Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ¹⁰Sengkang General Hospital, Singapore, Singapore, ¹¹Sengkang General Hospital / Singhealth, Singapore, Singapore, ¹²KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, ¹³KK Women's and Children's Hospital, Singapore, Singapore, ¹⁴Alexandra Hospital, Singapore, Singapore, ¹⁵Changi General Hospital, Singapore, Singapore, ¹⁶Khoo Teck Puat Hospital, Singapore, Singapore
Background/Purpose: Published data suggest no increased rate of flare of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination; however, the studies are limited by…
Abstract Number: 0988 • ACR Convergence 2022
Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran
Sathej Gopalakrishnan¹, Axel Krebs-Brown², Marco Nogueira Filho¹, Yoshihiro Kuroki³, Angelika Bachmann¹, Andreas Becker¹, Frank Schippers⁴, Markus Fluck¹, Özkan Yalkinoglu¹, Christine Kleinmond⁵, Denesh Chitkara⁶, Cristina Vazquez Mateo⁷, Sanjeev Roy⁸ and Lena Klopp-Schulze¹, ¹Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany, ²Global Biostatistics, the healthcare business of Merck KGaA, Darmstadt, Germany, ³Translational Medicine, Merck Biopharma Co., Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, Tokyo, Japan, ⁴Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁵Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Global Clinical Development, EMD Serono, Billerica, MA, ⁷Global Clinical Development, EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ⁸Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany
Background/Purpose: Enpatoran, a novel, highly selective and potent dual toll-like receptor (TLR) 7 and TLR8 inhibitor, is in development for the treatment of autoimmune disorders…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].